After 11 years at Business Partner Building in Wageningen, Innosieve Diagnostics BV has moved to a new location! This new location at Costerweg 1A in Wageningen offers a better fit for the laboratory and office needs of Innosieve.

We have attended, as exhibitor, the well-known Pharmalab Congress 2022, held November 22 and 23 in Dusseldorf. It was a very interesting Congress with many well-known visitors. It was for sure very nice to meet all face to face again!

We are proud our Next Generation Rapid Microbial Method, the Muscan, has been validated for bioburden testing, including GMP software that is fully CFR21 Part11 supportive. To offer an easy access to a RMM like the MuScan, we provide now the option of lease. Low monthly costs, maximum gain!

After extensive studies the Sieve-ID^(TM) Total Viable Count kit with MuScan^(TM) analysis was found to be at least equal to the compendial method according to USP[1223] and Ph.Eur 5.1.6 for the direct detection and enumeration of viable microbes. The comparison of a growth-based method with a direct method has given Innosieve much insight in best method validation approaches.

We are proud to announce that the MuScan^(TM) software meets 21 CFR part 11 compliancy. The software has a main focus on full digital processing and handling for optimal user friendliness while safeguarding your process and data.

To align with the growth of Innosieve Diagnostics BV the contract with Kadans Vastgoed BV was extended. Innosieve Diagnostics BV has now doubled its space in housing to meet development and production needs.

Innosieve Diagnostics BV has acquired the activities and intellectual properties of Lumibyte BV, subsidiary of Sioux BV. By acquisition of Lumibyte BV, Innosieve Diagnostics BV has now full ownership of all intellectual property of the MuScan^(TM) device.